Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | DGKA | P23743 | 3/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ritanserin SCHEMBL10598671 | 0.99 | MAPT (0.98) | MAPTCYP2D6TSHRDGKAPKM | |
| Ritanserin SCHEMBL11084340 | 0.96 | MAPT (0.93) | MAPTCYP2D6TSHRDGKAPKM | |
| SCHEMBL316891 | 0.96 | MAPT (1.00) | MAPTCYP2D6TSHRDGKAPKM | |
| Ritanserin SCHEMBL11084334 | 0.96 | MAPT (0.93) | MAPTCYP2D6TSHRDGKAPKM | |
| Hydrochloric Acid SCHEMBL10598175 | 0.96 | MAPT (0.98) | MAPTCYP2D6TSHRDGKAPKM | |
| Ritanserin SCHEMBL11034762 | 0.95 | MAPT (0.90) | MAPTCYP2D6TSHRDGKAPKM | |
| Ritanserin SCHEMBL10842786 | 0.94 | MAPT (0.88) | MAPTCYP2D6TSHRDGKAPKM | |
| Hydrochloric Acid SCHEMBL10845530 | 0.93 | MAPT (0.87) | MAPTCYP2D6TSHRDGKAPKM | |
| Ritanserin SCHEMBL8430142 | 0.85 | MAPT (0.73) | MAPTCYP2D6TSHRDGKAPKM | |
| SCHEMBL10919317 | 0.84 | HTR2C (0.73) | MAPTCYP2D6TSHRDGKAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5285 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| US-20260000641-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (IMDAI) | TERRAN BIOSCIENCES INC (US) | 2026-01-01 | — | — | US | claimed |
| US-20250332164-A1 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-10-30 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250235554-A1 | METHODS FOR IMPROVING ADENO-ASSOCIATED VIRUS (AAV) DELIVERY | NOVARTIS AG (CH) | 2025-07-24 | — | — | US | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | claimed |
| EP-0477624-A1 | Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors | E.R. SQUIBB & SONS, INC. (US) | 1992-04-01 | — | — | EP | claimed |
| EP-0477625-A1 | Method for preventing or treating anxiety employing a combination of an ace inhibitor and a drug that acts at serotonin receptors | E.R. SQUIBB & SONS, INC. (US) | 1992-04-01 | — | — | EP | claimed |
| US-5098889-A | Cognition activators, angiotensin converting enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1992-03-24 | — | — | US | claimed |
| WO-1992004014-A2 | REGULATION OF NEOPLASTIC CELL PROLIFERATION VIA A NOVEL 5HT1a RECEPTOR | MILES INC. (US) | 1992-03-19 | — | — | WO | claimed |
| WO-1992004015-A2 | REGULATION OF T-CELL PROLIFERATION VIA A NOVEL 5HT1a RECEPTOR | MILES INC. (US) | 1992-03-19 | — | — | WO | claimed |
| US-5032578-A | Administering inhibitors of angiotensin coverting enzyme to mammals | E. R. SQUIBB & SONS, INC. (US) | 1991-07-16 | — | — | US | claimed |
| WO-1991002527-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF CUTANEOUS, OCULAR, AND MUCOSAL HYPERSENSITIVITY, INFLAMMATION, AND HYPERPROLIFERATIVE CONDITIONS USING TOPICAL PREPARATIONS OF SEROTONIN ANTAGONISTS | BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1991-03-07 | — | — | WO | claimed |
| WO-1991002497-A1 | TOPICAL NIFEDIPINE FOR CUTANEOUS, OCULAR, MUCOSAL HYPERSENSITIVITY, INFLAMMATORY AND HYPERPROLIFERATIVE CONDITIONS | BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1991-03-07 | — | — | WO | claimed |
| US-4533665-A | SEROTONIN ANTAGONIST | JANSSEN PHARMACEUTICA (BE) | 1985-08-06 | — | — | US | claimed |
| EP-0110435-A1 | Novel ((bis(aryl)methylene)-1-piperidinyl)alkyl-pyrimidinones | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-06-13 | — | — | EP | claimed |